Skip to content
OpenCapital
Get started

Verrica Pharmaceuticals Inc. VRCA Q1 2026 earnings

Reported May 12, 2026 · After market close

Revenue$5.0MBeat by $508.8KDiluted EPS-$0.41Beat by $0.18
Revenue estimate$4.5M
EPS estimate-$0.59

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$5.9M
EPS estimate-$0.40

Versus estimates

Revenue

Q1 2026$5.0MBeat by $508.8K
Q4 2025$5.1MBeat by $572.0KQ3 2025$14.3MBeat by $9.8MQ2 2025$12.7MBeat by $6.3MQ1 2025$3.4MMiss by $93.7KQ4 2024$344.0KMiss by $1.8M

Diluted EPS

Q1 2026-$0.41Beat by $0.18
Q4 2025-$0.56Miss by $0.13Q3 2025$0.13Beat by $1.27Q2 2025$0.02Beat by $0.72Q1 2025-$1.00Beat by $0.40Q4 2024-$0.24Beat by $0.01

Ask the moment Verrica Pharmaceuticals Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Verrica Pharmaceuticals Inc. report Q1 2026 earnings?
Verrica Pharmaceuticals Inc. (VRCA) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Verrica Pharmaceuticals Inc.'s Q1 2026 revenue and EPS?
Verrica Pharmaceuticals Inc. reported revenue of $5.0M and diluted EPS of $-0.41 for Q1 2026.
Did Verrica Pharmaceuticals Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $4.5M by $508.8K. EPS beat the consensus estimate of $-0.59 by $0.18.
How did Verrica Pharmaceuticals Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 46.1% from $3.4M a year earlier and diluted EPS grew 59.0% from $-1.00.
Where can I find Verrica Pharmaceuticals Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219395) and the 10-Q periodic report (0001660334-26-000014) directly on SEC EDGAR. The filing index links above go to sec.gov.